128 related articles for article (PubMed ID: 18047852)
21. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R
Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARalpha and PPARgamma agonist activity.
Fracchiolla G; Laghezza A; Piemontese L; Carbonara G; Lavecchia A; Tortorella P; Crestani M; Novellino E; Loiodice F
ChemMedChem; 2007 May; 2(5):641-54. PubMed ID: 17357171
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.
Monsalve FA; Pyarasani RD; Delgado-Lopez F; Moore-Carrasco R
Mediators Inflamm; 2013; 2013():549627. PubMed ID: 23781121
[TBL] [Abstract][Full Text] [Related]
24. Peroxisome proliferator activated receptor-α agonists suppress transforming growth factor-α-induced matrix metalloproteinase-9 expression in human keratinocytes.
Meissner M; Berlinski B; Gille J; Doll M; Kaufmann R
Clin Exp Dermatol; 2011 Dec; 36(8):911-4. PubMed ID: 21790722
[TBL] [Abstract][Full Text] [Related]
25. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.
Sertznig P; Seifert M; Tilgen W; Reichrath J
J Cell Physiol; 2007 Jul; 212(1):1-12. PubMed ID: 17443682
[TBL] [Abstract][Full Text] [Related]
26. Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo.
Kane CD; Stevens KA; Fischer JE; Haghpassand M; Royer LJ; Aldinger C; Landschulz KT; Zagouras P; Bagley SW; Hada W; Dullea R; Hayward CM; Francone OL
Mol Pharmacol; 2009 Feb; 75(2):296-306. PubMed ID: 18971326
[TBL] [Abstract][Full Text] [Related]
27. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions.
Feige JN; Gelman L; Michalik L; Desvergne B; Wahli W
Prog Lipid Res; 2006 Mar; 45(2):120-59. PubMed ID: 16476485
[TBL] [Abstract][Full Text] [Related]
28. Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease?
Denning GM; Stoll LL
Pediatr Pulmonol; 2006 Jan; 41(1):23-34. PubMed ID: 16267824
[TBL] [Abstract][Full Text] [Related]
29. Peroxisome proliferator-activated receptors and the metabolic syndrome.
Bragt MC; Popeijus HE
Physiol Behav; 2008 May; 94(2):187-97. PubMed ID: 18191967
[TBL] [Abstract][Full Text] [Related]
30. Peroxisome proliferator-activated receptors mediate pleiotropic actions of statins.
Paumelle R; Staels B
Circ Res; 2007 May; 100(10):1394-5. PubMed ID: 17525375
[No Abstract] [Full Text] [Related]
31. Narrowing in on cardiovascular disease: the atheroprotective role of peroxisome proliferator-activated receptor gamma.
Gerry JM; Pascual G
Trends Cardiovasc Med; 2008 Feb; 18(2):39-44. PubMed ID: 18308193
[TBL] [Abstract][Full Text] [Related]
32. Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, re-exploring secondary organ complications of spontaneously hypertensive rats.
Sun L; Ke Y; Zhu CY; Tang N; Tian DK; Gao YH; Zheng JP; Bian K
Chin Med J (Engl); 2008 Nov; 121(22):2305-11. PubMed ID: 19080338
[TBL] [Abstract][Full Text] [Related]
33. Role of peroxisome proliferator-activated receptor alpha activation in acute myocardial damage induced by isoproterenol in rats.
Yuan J; Wu J; Hang ZG; Zhong XK; Zhou LW; Yu B
Chin Med J (Engl); 2008 Aug; 121(16):1569-73. PubMed ID: 18982870
[TBL] [Abstract][Full Text] [Related]
34. Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.
Bouhlel MA; Staels B; Chinetti-Gbaguidi G
J Intern Med; 2008 Jan; 263(1):28-42. PubMed ID: 18042221
[TBL] [Abstract][Full Text] [Related]
35. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism.
Biscetti F; Gaetani E; Flex A; Aprahamian T; Hopkins T; Straface G; Pecorini G; Stigliano E; Smith RC; Angelini F; Castellot JJ; Pola R
Diabetes; 2008 May; 57(5):1394-404. PubMed ID: 18268046
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists down-regulate alpha2-macroglobulin expression by a PPARalpha-dependent mechanism.
González MC; Corton JC; Cattley RC; Herrera E; Bocos C
Biochimie; 2009 Aug; 91(8):1029-35. PubMed ID: 19497347
[TBL] [Abstract][Full Text] [Related]
37. Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis.
Jakel H; Fruchart-Najib J; Fruchart JC
Drug News Perspect; 2006 Mar; 19(2):91-7. PubMed ID: 16628264
[TBL] [Abstract][Full Text] [Related]
38. [Peroxisome proliferator-activated receptor alpha, gamma and the dual agonists and atherosclerosis].
Chen LH; Yang GR; Guan YF
Sheng Li Ke Xue Jin Zhan; 2007 Apr; 38(2):153-5. PubMed ID: 17633233
[No Abstract] [Full Text] [Related]
39. [Gene-diet interactions in atherogenic dyslipidemias (part 2)].
Zák A; Slabý A
Cas Lek Cesk; 2007; 146(12):902-8. PubMed ID: 18257402
[TBL] [Abstract][Full Text] [Related]
40. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
Leisewitz AV; Urrutia CR; Martinez GR; Loyola G; Bronfman M
J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
